Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 6.6c

Immunosuppression Use for Induction by Steroid Use at Discharge, 2003 to 2007

Recipients with Pancreas Transplant Alone (PTA) Transplants

  No Steroids Used for Maintenance Steroids Used for Maintenance
N % N %
Functioning Graft with Immunosuppression Info at Discharge 386 100.0% 434 100.0%
Induction Drugs        
Atgam/NRATG/NRATS 3 0.8% 5 1.2%
OKT3 5 1.3% 12 2.8%
Thymoglobulin 215 55.7% 153 35.3%
Zenapax 11 2.8% 54 12.4%
Simulect 4 1.0% 17 3.9%
Campath 180 46.6% 58 13.4%
Rituximab 7 1.8% 1 0.2%
No Induction Drug Reported 38 9.8% 150 34.6%


Source: OPTN/SRTR Data as of May 1, 2008.

Includes patients with a functioning graft at discharge.

Steroids used for induction are not counted.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.



PDF FormatRequires Adobe Acrobat Reader